High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In Patients
US-2024269076-A1 · Aug 15, 2024 · US
Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
US11077139B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11077139-B2 |
| Application number | US-201415107749-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 30, 2014 |
| Priority date | Dec 30, 2013 |
| Publication date | Aug 3, 2021 |
| Grant date | Aug 3, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for reversing, alleviating, or inhibiting the progress of acute myeloid leukemia (AML) driven by mutation of the NPM-1 gene in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one arsenic compound and a therapeutically effective amount of at least one retinoid, wherein the subject has a normal karyotype, wherein the therapeutically effective amount of the at least one arsenic compound provides a serum concentration of 0.1 μM to 1 μM, wherein the therapeutically effective amount of the at least one retinoid provides a serum concentration of 0.3 μM to 1 μM, wherein the subject is not receiving chemotherapy prior to said administering step, and wherein the at least one arsenic compound is arsenic trioxide (As 2 O 3 ) and the at least one retinoid is a retinoic acid. 2. The method of claim 1 , wherein the ratio of As 2 O 3 to retinoic acid administered to the subject is from 1:1 to 1:3. 3. A method for reversing, alleviating, or inhibiting the progress of acute myeloid leukemia (AML) driven by mutation of the NPM-1 gene in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one arsenic compound and a therapeutically effective amount of at least one retinoid, wherein the subject has a normal karyotype, wherein the therapeutically effective amount of the at least one arsenic compound provides a serum concentration of 0.1 μM to 1 μM, wherein the therapeutically effective amount of the at least one retinoid provides a serum concentration of 0.3 μM to 1 μM, wherein the at least one arsenic compound and the at least one retinoid are administered without any other chemotherapeutic agent, and wherein the at least one arsenic compound is arsenic trioxide (As 2 O 3 ) and the at least one retinoid is a retinoic acid. 4. The method of claim 3 , wherein the ratio of As 2 O 3 to retinoic acid administered to the subject is from 1:1 to 1:3.
Assignees
Inventors
Classifications
containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title
- A61K33/36Primary
Arsenic; Compounds thereof · CPC title
Retinoic acids {; Salts thereof} · CPC title
specific for leukemia · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11077139B2 cover?
- The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically e…
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med, Univ Paris Diderot—Paris 7, Centre Nat Rech Scient, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K33/36. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).